Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

INOVIQ - Appendix 4C & Quarterly Activities Report - December 2022 (ASX:IIQ)

Highlights -- INOVIQ kicked off EXO-NET sales campaign in the US and reverted to a direct distribution model for hTERT sales in the US -- Contract Research Agreement signed with Nicoya to develo...read more

Immutep Quarterly Activities Report and Appendix 4C (ASX:IMM)

-- Second US FDA Fast Track designation granted to eftilagimod alpha (efti) supporting planned late-stage development in 1st line non-small cell lung cancer (1L NSCLC) -- Compelling Phase II result...read more

Notification of cessation of securities - IMM (ASX:IMM)

To view the notification, download the attached PDF.

Immutep - TACTI-003 trial 50% enrolment milestone has been achieved (ASX:IMM)

SYDNEY, AUSTRALIA – 4 January 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...read more

Immutep - Update on MBC trial design following successful FDA meeting (ASX:IMM)

-- Agreement with FDA on Phase II/III trial design positions the Company to exploit eftilagimod alpha’s potential to address high unmet need for metastatic breast cancer patients -- Patient p...read more

Immutep - Change of Director's Interest Notice L Turnbull (ASX:IMM)

To view the notice, download the attached PDF.

Immutep - Change of Director's Interest Notice - P Meyers (ASX:IMM)

To view the notice, download the attached PDF.

Immutep - Change of Director's Interest Notice - R Howard (ASX:IMM)

To view the notice, download the attached PDF.

Application for quotation of securities - IMM (ASX:IMM)

To view the application, download the attached PDF.

Immutep - Notification regarding unquoted securities - IMM (ASX:IMM)

To view the notification, download the attached PDF.

Notification regarding unquoted securities - IMM (ASX:IMM)

To view the notification, download the attached PDF.

Proposed issue of securities - IMM (ASX:IMM)

To view the notification, download the attached PDF.

INOVIQ - Positive EXO-NET Results in Ovarian Cancer (ASX:IIQ)

-- EXO-NET® feasibility study completed by The University of Queensland, confirms the utility of EXO-NET for isolating Extracellular Vesicle (EV) biomarkers and development of an EV-based ovaria...read more

Immutep - Commercial Scale in Manufacturing of Efti Achieved (ASX:IMM)

SYDNEY, AUSTRALIA – 8 December, 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing nov...read more

Immutep - GMP Manufacturing Process Developed for IMP761 LAG-3 Agonist (ASX:IMM)

SYDNEY, AUSTRALIA – 06 December 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing nov...read more

Viewing: 151 - 165 of 200 Previous | Next